POLISCOPE
Back to feed
NewsSan Diego Business JournalAugust 31, 2026San Diego

Revelation Biosciences evaluates Gemini drug candidate for kidney disease and infection treatments

Revelation Biosciences is testing its proprietary drug candidate, Gemini, to treat acute kidney injury, chronic kidney disease, post-surgical infections, and hyperinflammation from severe burns. The company is currently in the clinical-stage development phase for these multiple medical conditions.

biotechnologymedical researchkidney diseaseclinical trials
Read the full story at San Diego Business Journal

Why It Matters

This development represents the ongoing clinical evaluation of a new pharmaceutical candidate that could potentially impact treatment options for patients suffering from kidney disease and severe burn-related infections.

Key Facts

  • Revelation Biosciences is a clinical-stage biotechnology company.
  • The company is developing a proprietary drug candidate named Gemini.
  • Gemini is being evaluated for the treatment of acute kidney injury.
  • Gemini is being evaluated for the treatment of chronic kidney disease.
  • Gemini is being evaluated for the treatment of post-surgical infections.
  • Gemini is being evaluated for the treatment of hyperinflammation and infection associated with severe burns.

Who's Mentioned

otherREVB“Nasdaq stock ticker symbol for Revelation Biosciences.”organizationRevelation Biosciences“A clinical-stage biotechnology company developing the Gemini drug candidate.”locationSan Diego“Location of the company headquarters.”